

02-28-00

Patent Application  
Attorney Docket No. PC 9919ARTRIN THE UNITED STATES PATENT AND TRADEMARK OFFICEAssistant Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231jc511 U.S. PTO  
09/512914  
02/25/00REQUEST FOR FILING AND  
TRANSMITTAL OF UTILITY PATENT APPLICATION  
PURSUANT TO 35 U.S.C. §111 and 37 C.F.R. §1.51 ET SEQ

Sir:

This is a request for filing the utility patent application, transmitted herewith, of

Inventors: Jan Buch and Robert Andrew Donald ScottTitle: Therapeutic Combination

Enclosed are also:

- ☐ \_\_\_\_\_ sheets of drawing(s).
- ☐ An assignment of the invention to \_\_\_\_\_  
(Fee for recordal of assignment, pursuant to 37 C.F.R. § 1.21(h), \$40.00).
- ☐ A certified copy of a \_\_\_\_\_  
application.
- ☐ A Declaration and Power of Attorney.
- ☒ A Disclosure Statement, Form FB-A820, and copy(ies) of the reference(s) cited.
- ☒ This application claims priority from copending International Application No. PCT/IB98/01225, filed August 11, 1998, and also claims priority from United States Provisional Application No. 60/057,275, filed August 29, 1997.
- ☒ This application is being filed without a Declaration and Power of Attorney. The undersigned attorney/agent has been authorized to file the subject application on behalf of the inventor(s). All correspondence should be sent to Gregg C. Benson, Pfizer Inc., Eastern Point Road, Box 519, Groton, CT 06340.

EXPRESS MAIL NO. 2504820588205

The inventors are:

(name) Jan Buch  
a resident of (city, state, country) Greenwich, CT, USA  
and a citizen of (country) Denmark

(name) Robert Andrew Donald Scott  
a resident of (city, state, country) Riverside, CT, USA  
and a citizen of (country) South Africa

BASIC APPLICATION FEE: \$690.00  
CLAIMS FEES:

CLAIMS AS FILED

Total Claims	<u>117</u>	-20=	<u>97</u>	x \$18.00	<u>1,746.00</u>
Independent Claims	<u>19</u>	- 3=	<u>16</u>	x \$78.00	<u>1,248.00</u>
<input type="checkbox"/> Multiple Dependent Claim(s) fee				\$260.00	
Total Filing Fee					<u>\$3,684.00</u>

- ☒ Please charge Deposit Account No. 16-1445 in the amount of \$3,684.00. Two copies of this paper are enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. §§ 1.16 and 1.17 by the filing of this paper, or credit any overpayment, to Deposit Account No 16-1445. Two copies of this paper are enclosed.

Respectfully submitted,

Date: February 25, 2000

Robert T. Rohau  
Robert T. Rohau  
Attorney for Applicant(s)  
Reg. No. 36,257

Pfizer Inc.  
Patent Department, Box 519  
Eastern Point Road  
Groton, CT 06340  
(860) 441-5910

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jan Buch, et al.

SERIAL NO.: To Be Assigned

Examiner: To Be Assigned

Art Unit: To Be Assigned

FILED: Herewith

FOR: Therapeutic Combination

Assistant Commissioner For Patents  
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

In the matter of the application being filed herewith, please amend the application as follows:

In the specification:


Please enter the following sentence as the first paragraph in the specification, immediately following the title:

-- This application claims priority from copending International Patent Application Number PCT/IB98/01225, filed August 11, 1998, which is a continuation of U.S. Provisional Application No. 60/057,275, filed August 29, 1997.--

A Notice of Allowance is courteously solicited.

Date: *February 25, 2000*

Respectfully Submitted,

  
 Robert T. Ropau  
 Attorney for Applicants  
 Reg. No. 36,257

 Pfizer Inc.  
 Patent Department  
 Eastern Point Road  
 Groton, Connecticut 06340  
 860-441-5910
**EXPRESS MAIL NO. 9524820588205**


### THERAPEUTIC COMBINATION

This invention relates to pharmaceutical combinations of amlodipine and pharmaceutically acceptable acid addition salts thereof and atorvastatin and pharmaceutically acceptable salts thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those additive and synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms or signs of cardiac risk, including humans.


### BACKGROUND OF THE INVENTION

The conversion of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate is an early and rate-limiting step in the cholesterol biosynthetic pathway. This step is catalyzed by the enzyme HMG-CoA reductase. Statins inhibit HMG-CoA reductase from catalyzing this conversion. As such, statins are collectively potent lipid lowering agents.

Atorvastatin calcium, disclosed in U.S. Patent No. 5,273,995, which is incorporated herein by reference, is currently sold as Lipitor<sup>®</sup> and has the formula




Atorvastatin calcium is a selective, competitive inhibitor of HMG-CoA. As such, atorvastatin calcium is a potent lipid lowering compound. The free carboxylic acid form of atorvastatin exists predominantly as the lactone of the formula



and is disclosed in U.S. Patent No. 4,681,893, which is incorporated herein by reference.

Amlodipine and related dihydropyridine compounds are disclosed in U.S. Patent No. 4,572,909, which is incorporated herein by reference, as potent anti-ischemic and antihypertensive agents. U.S. Patent No. 4,879,303, which is incorporated herein by reference, discloses amlodipine benzenesulfonate salt (also termed amlodipine besylate). Amlodipine and amlodipine besylate are potent and long lasting calcium channel blockers. As such, amlodipine, amlodipine besylate and other pharmaceutically acceptable acid addition salts of amlodipine have utility as antihypertensive agents and as antiischemic agents. Amlodipine and its pharmaceutically acceptable acid addition salts are also disclosed in U.S. Patent No. 5,155,120 as having utility in the treatment of congestive heart failure. Amlodipine besylate is currently sold as Norvasc®. Amlodipine has the formula



Atherosclerosis is a condition characterized by irregularly distributed lipid deposits in the intima of arteries, including coronary, carotid and peripheral arteries.

Atherosclerotic coronary heart disease (hereinafter termed "CHD") accounts for 53% of all deaths attributable to a cardiovascular event. CHD accounts for nearly one-half (about \$50-60 billion) of the total U.S. cardiovascular healthcare expenditures and about 6% of the overall national medical bill each year. Despite attempts to modify secondary risk factors such as, *inter alia*, smoking, obesity and lack of exercise, and treatment of dyslipidemia with dietary modification and drug therapy, CHD remains the most common cause of death in the United States.

High levels of blood cholesterol and blood lipids are conditions involved in the onset of atherosclerosis. It is well known that inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) are effective in lowering the level of blood plasma cholesterol, especially low density lipoprotein cholesterol (LDL-C), in man (Brown and Goldstein, New England Journal of Medicine, 1981, 305, No. 9, 515-517). It has now been established that lowering LDL-C levels affords protection from coronary heart disease (see, e.g., The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 1994, 344, 1383-89; and Shepherd, J. et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, New England Journal of Medicine, 1995, 333, 1301-07).

Angina pectoris is a severe constricting pain in the chest, often radiating from the precordium to the left shoulder and down the left arm. Often angina pectoris is due to ischemia of the heart and is usually caused by coronary disease.

Currently the treatment of symptomatic angina pectoris varies significantly from country to country. In the U.S., patients who present with symptomatic, stable angina pectoris are frequently treated with surgical procedures or PTCA. Patients who undergo PTCA or other surgical procedures designed to treat angina pectoris frequently experience complications such as restenosis. This restenosis may be manifested either as a short term proliferative response to angioplasty-induced trauma or as long term progression of the atherosclerotic process in both graft vessels and angioplasted segments.

The symptomatic management of angina pectoris involves the use of a number of drugs, frequently as a combination of two or more of the following classes: beta blockers, nitrates and calcium channel blockers. Most, if not all, of these patients require therapy with a lipid lowering agent as well. The National Cholesterol Education

Program (NCEP) recognizes patients with existing coronary artery disease as a special class requiring aggressive management of raised LDL-C.

Amlodipine helps to prevent myocardial ischemia in patients with exertional angina pectoris by reducing Total Peripheral Resistance, or afterload, which reduces the rate pressure product and thus myocardial oxygen demand at any particular level of exercise. In patients with vasospastic angina pectoris, amlodipine has been demonstrated to block constriction and thus restore myocardial oxygen supply. Further, amlodipine has been shown to increase myocardial oxygen supply by dilating the coronary arteries.

Hypertension frequently coexists with hyperlipidemia and both are considered to be major risk factors for developing cardiac disease ultimately resulting in adverse cardiac events. This clustering of risk factors is potentially due to a common mechanism. Further, patient compliance with the management of hypertension is generally better than patient compliance with hyperlipidemia. It would therefore be advantageous for patients to have a single therapy which treats both of these conditions.

Coronary heart disease is a multifactorial disease in which the incidence and severity are affected by the lipid profile, the presence of diabetes and the sex of the subject. Incidence is also affected by smoking and left ventricular hypertrophy which is secondary to hypertension. To meaningfully reduce the risk of coronary heart disease, it is important to manage the entire risk spectrum. For example, hypertension intervention trials have failed to demonstrate full normalization in cardiovascular mortality due to coronary heart disease. Treatment with cholesterol synthesis inhibitors in patients with and without coronary artery disease reduces the risk of cardiovascular morbidity and mortality.

The Framingham Heart Study, an ongoing prospective study of adult men and women, has shown that certain risk factors can be used to predict the development of coronary heart disease. (see Wilson et al., Am. J. Cardiol. **1987**, **59**(14):91G-94G). These factors include age, gender, total cholesterol level, high density lipoprotein (HDL) level, systolic blood pressure, cigarette smoking, glucose intolerance and cardiac enlargement (left ventricular hypertrophy on electrocardiogram, echocardiogram or enlarged heart on chest X-ray). Calculators and computers can easily be programmed using a multivariate logistic function that allows calculation of the conditional probability

of cardiovascular events. These determinations, based on experience with 5,209 men and women participating in the Framingham study, estimate coronary artery disease risk over variable periods of follow-up. Modeled incidence rates range from less than 1% to greater than 80% over an arbitrarily selected six year interval. However, these rates are typically less than 10% and rarely exceed 45% in men and 25% in women.

Kramsch et al., *Journal of Human Hypertension* (1995) (Suppl. 1), 53-59 disclose the use of calcium channel blockers, including amlodipine, to treat atherosclerosis. That reference further suggests that atherosclerosis can be treated with a combination of amlodipine and a lipid lowering agent. Human trials have shown that calcium channel blockers have beneficial effects in the treatment of early atherosclerotic lesions. (see, e.g., Lichtlen, P.R. et al., Retardation of angiographic progression o coronary artery disease by nifedipine, *Lancet*, 1990, 335, 1109-13; and Waters, D. et al., A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis, *Circulation*, 1990, 82, 1940-53.) U.S. 4,681,893 discloses that certain statins, including atorvastatin, are hypolipidemic agents and as such are useful in treating atherosclerosis. Jukema et al., *Circulation*, 1995 (Suppl. 1), 1-197, disclose that there is evidence that calcium channel blockers act synergistically in combination with lipid lowering agents (e.g., HMG-CoA reductase inhibitors), specifically pravastatin. Orekhov et al., *Cardiovascular Drugs and Therapy*, 1997, 11, 350 disclose the use of amlodipine in combination with lovastatin for the treatment of atherosclerosis.



### SUMMARY OF THE INVENTION

This invention is directed to a pharmaceutical composition, hereinafter termed "Composition A", comprising:

- a. an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof;
- b. an amount of atorvastatin or a pharmaceutically acceptable salt thereof; and
- c. a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a pharmaceutical composition, hereinafter termed "Composition AA", of Composition A comprising amlodipine besylate.

This invention is more particularly directed to a pharmaceutical composition, hereinafter termed "Composition AB", of Composition AA comprising the hemicalcium salt of atorvastatin.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition B", for use with a second pharmaceutical composition for achieving an antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the sum of the antihypertensive and hypolipidemic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition BA", of Composition B wherein said second pharmaceutical composition comprises amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed "Composition BB", of Composition BA comprising the hemicalcium salt of atorvastatin.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition C", for use with a second pharmaceutical composition for

achieving an antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the sum of the antihypertensive and hypolipidemic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition CA", of Composition C comprising amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed "Composition CB", of Composition CA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition D", for use with a second pharmaceutical composition for achieving an antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the antihypertensive and hypolipidemic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition DA", of Composition D comprising amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed "Composition DB", of Composition DA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition E", for use with a second pharmaceutical composition for achieving an antihypertensive effect and a hypolipidemic effect in a mammal suffering

from hypertension and hyperlipidemia, which effects are greater than the antihypertensive and hypolipidemic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition EA", of Composition E wherein said second pharmaceutical composition comprises amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed "Composition EB" of Composition EA comprising the hemicalcium salt of atorvastatin.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition F", for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the sum of the antianginal effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition FA", of Composition F comprising amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed "Composition FB", of Composition FA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition G", for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which

effect is greater than the sum of the antiangina effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition GA", of Composition G wherein said second pharmaceutical composition comprises amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed "Composition GB", of Composition G comprising the hemicalcium salt of atorvastatin.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition H", for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the antianginal effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition HA", of Composition H comprising amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed "Composition HB", of Composition HA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition J", for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the antianginal effects achieved by administering said first or

second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition JA", of Composition J wherein said second pharmaceutical composition comprises amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed "Composition JB", of Composition JA comprising the hemicalcium salt of atorvastatin.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition K", for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the sum of the antiatherosclerotic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition KA", of Composition K wherein said second pharmaceutical composition comprises amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed "Composition KB", of Composition KA comprising the hemicalcium salt of atorvastatin.

This invention is still more particularly directed to a composition, hereinafter termed "Composition KC", of Composition KB wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.

This invention is still more particularly directed to a composition of Composition KC wherein said progression of atherosclerotic plaques is slowed in coronary arteries.

This invention is also particularly directed to a composition of Composition KB wherein said progression of atherosclerotic plaques is slowed in carotid arteries.

This invention is also particularly directed to a composition of Composition KB wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.

This invention is more particularly directed to a composition, hereinafter termed "Composition KD", of Composition KB wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.

This invention is still more particularly directed to a composition of Composition KD wherein said regression of atherosclerotic plaques occurs in coronary arteries.

This invention is also particularly directed to a composition of Composition KD wherein said regression of atherosclerotic plaques occurs in carotid arteries.

This invention is also particularly directed to a composition of Composition KD wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition L", for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the sum of the antiatherosclerotic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition LA", of Composition L comprising amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed "Composition LB", of Composition LA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

This invention is still more particularly directed to a composition, hereinafter termed "LC", of Composition LB wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.

This invention is still more particularly directed to a composition of Composition LC wherein said progression of atherosclerotic plaques is slowed in coronary arteries.

This invention is also particularly directed to a composition of Composition LC wherein said progression of atherosclerotic plaques is slowed in carotid arteries.

This invention is also particularly directed to a composition of Composition LC wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.

This invention is more particularly directed to a composition, hereinafter termed "Composition LD", of Composition LB wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.

This invention is still more particularly directed to a composition of Composition LD wherein said regression of atherosclerotic plaques occurs in coronary arteries.

This invention is also particularly directed to a composition of Composition LD wherein said regression of atherosclerotic plaques occurs in carotid arteries.

This invention is also particularly directed to a composition of Composition LD wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition M", for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the antiatherosclerotic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition MA", of Composition M comprising amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed "Composition MB", of Composition MA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

This invention is still more particularly directed to a composition, hereinafter termed "Composition MC", of Composition MB wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.

This invention is still more particularly directed to a composition of Composition MC wherein said progression of atherosclerotic plaques is slowed in coronary arteries.

This invention is also particularly directed to a composition of Composition MC wherein said progression of atherosclerotic plaques is slowed in carotid arteries.

This invention is also particularly directed to a composition of Composition MC wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.

This invention is more particularly directed to a composition, hereinafter termed "Composition MD", of Composition MB wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.

This invention is still more particularly directed to a composition of Composition MD wherein said regression of atherosclerotic plaques occurs in coronary arteries.

This invention is also particularly directed to a composition of Composition MD wherein said regression of atherosclerotic plaques occurs in carotid arteries.

This invention is also particularly directed to a composition of Composition MD wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition N", for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the antiatherosclerotic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition NA", of Composition N wherein said second pharmaceutical composition comprises amlodipine besylate.



This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed "Composition NB", of Composition NA comprising the hemicalcium salt of atorvastatin.

This invention is still more particularly directed to a composition, hereinafter termed "Composition NC", of Composition NB wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.

This invention is still more particularly directed to a composition of Composition NC wherein said progression of atherosclerotic plaques is slowed in coronary arteries.

This invention is also particularly directed to a composition of Composition NC wherein said progression of atherosclerotic plaques is slowed in carotid arteries.

This invention is also particularly directed to a composition of Composition NC wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.

This invention is more particularly directed to a composition, hereinafter termed "Composition ND", of Composition NB wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.

This invention is still more particularly directed to a composition of Composition ND wherein said regression of atherosclerotic plaques occurs in coronary arteries.

This invention is also particularly directed to a composition of Composition ND wherein said regression of atherosclerotic plaques occurs in carotid arteries.

This invention is also particularly directed to a composition of Composition ND wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition P", for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the sum of the cardiac risk management effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition PA", of Composition P comprising amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition of Composition PA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition Q", for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the sum of the cardiac risk management effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition QA", of Composition Q wherein said second pharmaceutical composition comprises amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition of Composition QA comprising the hemicalcium salt of atorvastatin.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition R", for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the cardiac risk management effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition RA", of Composition R comprising amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition of Composition RA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

This invention is also directed to a first pharmaceutical composition, hereinafter termed "Composition S", for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the cardiac risk management effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a first pharmaceutical composition, hereinafter termed "Composition SA", of Composition S wherein said second pharmaceutical composition comprises amlodipine besylate.

This invention is more particularly directed to a first pharmaceutical composition of Composition S comprising the hemicalcium salt of atorvastatin.

This invention is also directed to a kit, hereinafter termed "Kit A", for achieving a therapeutic effect in a mammal comprising:

- a. an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent in a first unit dosage form;
- b. an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and
- c. container means for containing said first and second dosage forms.

This invention is particularly directed to a kit, hereinafter termed "Kit AA", of Kit A comprising amlodipine besylate.

This invention is more particularly directed to a kit, hereinafter termed "Kit AB", of Kit AA comprising the hemicalcium salt of atorvastatin.

This invention is still more particularly directed to a kit, hereinafter termed "Kit AC", of Kit AB wherein said therapeutic effect is treatment of hypertension and hyperlipidemia.

This invention is still more particularly directed to a kit, hereinafter termed "Kit AD", of Kit AB wherein said therapeutic effect is treatment of angina pectoris.

This invention is also particularly directed to a kit, hereinafter termed "Kit AE", of Kit AB wherein said therapeutic effect is management of cardiac risk.

This invention is also particularly directed to a kit, hereinafter termed "Kit AF", of Kit AB wherein said therapeutic effect is treatment of atherosclerosis.

This invention is still more particularly directed to a kit, hereinafter termed "Kit AG", of Kit AF wherein said treatment of atherosclerosis slows the progression of atherosclerotic plaques.

This invention is further directed to a kit, hereinafter termed "Kit AH", of Kit AG wherein said progression of atherosclerotic plaques is slowed in coronary arteries.

This invention is still further directed to a kit, hereinafter termed "Kit AJ", of Kit AG wherein said progression of atherosclerotic plaques is slowed in carotid arteries.

This invention is still further directed to a kit, hereinafter termed "Kit AK", of Kit AG wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.

This invention is still further directed to a kit, hereinafter termed "Kit AL", of Kit AF wherein said treatment of atherosclerosis causes the regression of atherosclerotic plaques.

This invention is still further directed to a kit of Kit AL wherein said regression of atherosclerotic plaques occurs in coronary arteries.

This invention is still further directed to a kit of Kit AL wherein said regression of atherosclerotic plaques occurs in carotid arteries.

This invention is still further directed to a kit of Kit AL wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.

This invention is also directed to a method, hereinafter termed "Method A", for treating a mammal in need of therapeutic treatment comprising administering to said mammal

(a) an amount of a first compound, said first compound being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(b) an amount of a second compound, said second compound being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable carrier or diluent.

This invention is particularly directed to a method, hereinafter Method B, of Method A comprising amlodipine besylate.

This invention is more particularly directed to a method, hereinafter termed "Method C", of Method B comprising the hemicalcium salt of atorvastatin.

This invention is still more particularly directed to a method, hereinafter termed "Method D", of Method A wherein said first compound and said second compound are administered simultaneously.

This invention is still more particularly directed to a method, hereinafter termed "Method E", of Method A wherein said first compound and said second compound are administered sequentially in either order.

This invention is also particularly directed to a method, hereinafter termed "Method F", of Method C wherein said first compound and said second compound are administered simultaneously.

This invention is further directed to a method, hereinafter termed "Method G", of Method C wherein said first compound and said second compound are administered sequentially in either order.

This invention is still further directed to a method of Method A wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.

This invention is still further directed to a method of Method F wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.

This invention is still further directed to a method of Method G wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.

This invention is further directed to a method of Method A wherein said therapeutic treatment comprises antianginal treatment.

This invention is further directed to a method of Method F wherein said therapeutic treatment comprises antianginal treatment.

This invention is further directed to a method of Method G wherein said therapeutic treatment comprises antianginal treatment.

This invention is further directed to a method of Method A wherein said therapeutic treatment comprises cardiac risk management.

This invention is further directed to a method of Method F wherein said therapeutic treatment comprises cardiac risk management.

This invention is further directed to a method of Method G wherein said therapeutic treatment comprises cardiac risk management.

This invention is further directed to a method of Method A wherein said therapeutic treatment comprises antiatherosclerotic treatment.

This invention is further directed to a method of Method F wherein said therapeutic treatment comprises antiatherosclerotic treatment.

This invention is further directed to a method of Method G wherein said therapeutic treatment comprises antiatherosclerotic treatment.

Amlodipine is a racemic compound due to the symmetry at position 4 of the dihydropyridine ring. The R and S enantiomers may be prepared as described by Arrowsmith et al., J. Med. Chem., 1986, 29, 1696. The calcium channel blocking activity of amlodipine is substantially confined to the S(-) isomer and to the racemic mixture containing the R(+) and S(-) forms. (see International Patent Application Number PCT/EP94/02697). The R(+) isomer has little or no calcium channel blocking activity. However, the R(+) isomer is a potent inhibitor of smooth muscle cell migration. Thus, the R(+) isomer is useful in the treatment or prevention of atherosclerosis. (see International Patent Application Number PCT/EP95/00847). Based on the above, a skilled person could choose the R(+) isomer, the S(-) isomer or the racemic mixture of the R(+) isomer and the S(-) isomer for use in the combination of this invention.

Where used herein, the term "cardiac risk" means the likelihood that a subject will suffer a future adverse cardiac event such as, e.g., myocardial infarction, cardiac arrest, cardiac failure, cardiac ischaemia. Cardiac risk is calculated using the

Framingham Risk Equation as set forth above. The term "cardiac risk management" means that the risk of future adverse cardiac events is substantially reduced.

### DETAILED DESCRIPTION OF THE INVENTION

The pharmaceutical compositions of this invention comprise amlodipine or a pharmaceutically acceptable acid addition salt thereof and/or atorvastatin or a pharmaceutically acceptable salt thereof.

Amlodipine may readily be prepared as described in U.S. Patent No. 4,572,909 which is incorporated herein by reference. Amlodipine besylate, which is currently sold as Norvasc<sup>®</sup>, may be prepared as described in U.S. Patent No. 4,879,303, which is incorporated herein by reference. Amlodipine and amlodipine besylate are potent and long lasting calcium channel blockers.

The expression "pharmaceutically-acceptable acid addition salts" is intended to define but is not limited to such salts as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogenphosphate, acetate, besylate, succinate, citrate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.

Other acid addition salts of amlodipine may be prepared by reacting the free base form of amlodipine with the appropriate acid. When the salt is of a monobasic acid (e.g., the hydrochloride, the hydrobromide, the p-toluenesulfonate, the acetate), the hydrogen form of a dibasic acid (e.g., the hydrogen sulfate, the succinate) or the dihydrogen form of a tribasic acid (e.g., the dihydrogen phosphate, the citrate), at least one molar equivalent and usually a molar excess of the acid is employed. However when such salts as the sulfate, the hemisuccinate, the hydrogen phosphate or the phosphate are desired, the appropriate and exact chemical equivalents of acid will generally be used. The free base of amlodipine and the acid are usually combined in a co-solvent from which the desired salt precipitates, or can be otherwise isolated by concentration and/or addition of a non-solvent.

Atorvastatin may readily be prepared as described in U.S. Patent No. 4,681,892, which is incorporated herein by reference. The hemicalcium salt of atorvastatin, which is currently sold as Lipitor<sup>®</sup>, may readily be prepared as described in U.S. Patent No. 5,273,995, which is incorporated herein by reference.

The expression "pharmaceutically acceptable salts" includes both pharmaceutically acceptable acid addition salts and pharmaceutically acceptable cationic salts. The expression "pharmaceutically-acceptable cationic salts" is intended to define but is not limited to such salts as the alkali metal salts, (e.g. sodium and potassium), alkaline earth metal salts (e.g. calcium and magnesium), aluminum salts, ammonium salts, and salts with



organic amines such as benzathine (N,N'-dibenzylethylenediamine), choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), benethamine (N-benzylphenethylamine), diethylamine, piperazine, tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol) and procaine. The expression "pharmaceutically-acceptable acid addition salts" is intended to define but is not limited to such salts as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogenphosphate, acetate, succinate, citrate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.

Other pharmaceutically-acceptable cationic salts of atorvastatin may be readily prepared by reacting the free acid form of atorvastatin with an appropriate base, usually one equivalent, in a co-solvent. Typical bases are sodium hydroxide, sodium methoxide, sodium ethoxide, sodium hydride, potassium methoxide, magnesium hydroxide, calcium hydroxide, benzathine, choline, diethanolamine, piperazine and tromethamine. The salt is isolated by concentration to dryness or by addition of a non-solvent. In many cases, salts are preferably prepared by mixing a solution of the acid with a solution of a different salt of the cation (e.g., sodium or potassium ethylhexanoate, magnesium oleate) and employing a solvent (e.g., ethyl acetate) from which the desired cationic salt precipitates. The salts may also be isolated by concentrating the reaction solution and/or by adding a non-solvent.

The acid addition salts of atorvastatin may be readily prepared by reacting the free base form of atorvastatin with the appropriate acid. When the salt is of a monobasic acid (e.g., the hydrochloride, the hydrobromide, the p-toluenesulfonate, the acetate), the hydrogen form of a dibasic acid (e.g., the hydrogen sulfate, the succinate) or the dihydrogen form of a tribasic acid (e.g., the dihydrogen phosphate, the citrate), at least one molar equivalent and usually a molar excess of the acid is employed. However when such salts as the sulfate, the hemisuccinate, the hydrogen phosphate or the phosphate are desired, the appropriate and exact chemical equivalents of acid will generally be used. The free base and the acid are usually combined in a co-solvent from which the desired salt precipitates, or can be otherwise isolated by concentration and/or addition of a non-solvent.

In addition, amlodipine, pharmaceutically acceptable acid addition salts thereof, atorvastatin and pharmaceutically acceptable salts thereof may occur as hydrates or solvates. Said hydrates and solvates are also within the scope of the invention.

The pharmaceutical combinations and methods of this invention are all adapted to therapeutic use as agents in the treatment of atherosclerosis, angina pectoris, and a

condition characterized by the presence of both hypertension and hyperlipidemia in mammals, particularly humans. Further, since these diseases and conditions are closely related to the development of cardiac disease and adverse cardiac conditions, these combinations and methods, by virtue of their action as antiatherosclerotics, antianginals, antihypertensives and antihyperlipidemics, are useful in the management of cardiac risk.

The utility of the compounds of the present invention as medical agents in the treatment of atherosclerosis in mammals (e.g. humans) is demonstrated by the activity of the compounds of this invention in conventional assays and the clinical protocol described below:

Effect of Amlodipine and Atorvastatin, Alone  
and in Combination, on the Treatment  
of Atherosclerosis

This study is a prospective randomized evaluation of the effect of a combination of amlodipine and atorvastatin on the progression/regression of coronary and carotid artery disease. The study is used to show that a combination of amlodipine and atorvastatin is effective in slowing or arresting the progression or causing regression of existing coronary artery disease (CAD) as evidenced by changes in coronary angiography or carotid ultrasound, in subjects with established disease.

This study is an angiographic documentation of coronary artery disease carried out as a double-blind, placebo-controlled trial of a minimum of about 500 subjects and preferably of about 780 to about 1200 subjects. It is especially preferred to study about 1200 subjects in this study. Subjects are admitted into the study after satisfying certain entry criteria set forth below.

Entry criteria: Subjects accepted for entry into this trial must satisfy certain criteria. Thus the subject must be an adult, either male or female, aged 18-80 years of age in whom coronary angiography is clinically indicated. Subjects will have angiographic presence of a significant focal lesion such as 30% to 50% on subsequent evaluation by quantitative coronary angiography (QCA) in a minimum of one segment (non-PTCA, non-bypassed or non-MI vessel) that is judged not likely to require intervention over the next 3 years. It is required that the segments undergoing analysis have not been interfered with. Since percutaneous transluminal cardiac angioplasty (PTCA) interferes with segments by the

insertion of a balloon catheter, non-PTCA segments are required for analysis. It is also required that the segments to be analyzed have not suffered a thrombotic event, such as a myocardial infarct (MI). Thus the requirement for non-MI vessels. Segments that will be analyzed include: left main, proximal, mid and distal left anterior descending, first and second diagonal branch, proximal and distal left circumflex, first or largest space obtuse marginal, proximal, mid and distal right coronary artery. Subjects will have an ejection fraction of greater than 30% determined by catheterization or radionuclide ventriculography or ECHO cardiogram at the time of the qualifying angiogram or within the previous three months of the acceptance of the qualifying angiogram provided no intervening event such as a thrombotic event or procedure such as PTCA has occurred.

Generally, due to the number of patients and the physical limitations of any one facility, the study is carried out at multiple sites. At entry into the study, subjects undergo quantitative coronary angiography as well as B-mode carotid artery ultrasonography and assessment of carotid arterial compliance at designated testing centers. This establishes baselines for each subject. Once admitted into the test, subjects are randomized to receive amlodipine besylate (10 mgs) and placebo or atorvastatin calcium (80 mgs) and placebo or amlodipine besylate (10 mgs) and atorvastatin calcium (80 mgs). All doses set forth in this protocol are per day doses. The amount of amlodipine besylate may be varied as required. Generally, a subject will start out taking 10 mg and the amount will be titrated down to as little as 5 mg as determined by the clinical physician. The amount of atorvastatin calcium will similarly be titrated down from 80 mg if it is determined by the physician to be in the best interests of the subject. It will be recognized by a skilled person that the free base form or other salt forms of amlodipine besylate or the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of atorvastatin calcium and amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.

The subjects are monitored for a one to three year period, generally three years being preferred. B-mode carotid ultrasound assessment of carotid artery atherosclerosis and compliance are performed at regular intervals throughout the study.

Generally, six month intervals are suitable. Typically this assessment is performed using B-mode ultrasound equipment. However, a person skilled in the art may use other methods of performing this assessment. Coronary angiography is performed at the

conclusion of the one to three year treatment period. The baseline and post-treatment angiograms and the intervening carotid artery B-mode ultrasonograms are evaluated for new lesions or progression of existing atherosclerotic lesions. Arterial compliance measurements are assessed for changes from baseline and over the 6-month evaluation periods.

The primary objective of this study is to show that the combination of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof reduces the progression of atherosclerotic lesions as measured by quantitative coronary angiography (QCA) in subjects with clinical coronary artery disease. QCA measures the opening in the lumen of the arteries measured.

The primary endpoint of the study is the change in the average mean segment diameter of the coronary artery tree. Thus, the diameter of an arterial segment is measured at various portions along the length of that segment. The average diameter of that segment is then determined. After the average segment diameter of many segments has been determined, the average of all segment averages is determined to arrive at the average mean segment diameter. The mean segment diameter of subjects taking atorvastatin or pharmaceutically acceptable salts thereof and amlodipine or pharmaceutically acceptable acid addition salts thereof will decline more slowly, will be halted completely, or there will be an increase in the mean segment diameter. These results represent slowed progression of atherosclerosis, halted progression of atherosclerosis and regression of atherosclerosis, respectively.

The secondary objective of this study is to show that the combination of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically salt thereof reduces the rate of progression of atherosclerosis in the carotid arteries as measured by the slope of the maximum intimal-medial thickness measurements averaged over 12 separate wall segments (Mean Max) as a function of time, more than does amlodipine or a pharmaceutically acceptable acid addition salt thereof or atorvastatin or a pharmaceutically acceptable salt thereof alone. The intimal-medial thickness of subjects taking atorvastatin or a pharmaceutically acceptable salt thereof and amlodipine or a pharmaceutically acceptable acid addition salt thereof will increase more slowly, will cease to increase or will decrease. These results represent slowed progression of atherosclerosis, halted progression of atherosclerosis and regression of atherosclerosis, respectively.

The utility of the compounds of the present invention as medical agents in the treatment of angina pectoris in mammals (e.g., humans) is demonstrated by the activity of the compounds of this invention in conventional assays and the clinical protocol described below:

Effect of Amlodipine and Atorvastatin, Alone  
and in Combination, on the  
Treatment of Angina

This study is a double blind, parallel arm, randomized study to show the effectiveness of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof given in combination in the treatment of symptomatic angina.

**Entry criteria:** Subjects are males or females between 18 and 80 years of age with a history of typical chest pain associated with one of the following objective evidences of cardiac ischemia: (1) stress test segment elevation of about one millimeter or more from the ECG; (2) positive treadmill stress test; (3) new wall motion abnormality on ultrasound; or (4) coronary angiogram with a significant qualifying stenosis. Generally a stenosis of about 30-50% is considered to be significant.

Each subject is evaluated for about ten to thirty-two weeks. At least ten weeks are generally required to complete the study. Sufficient subjects are used in this screen to ensure that about 200 to 800 subjects and preferably about 400 subject are evaluated to complete the study. Subjects are screened for compliance with the entry criteria, set forth below, during a four week run in phase. After the screening criteria are met, subjects are washed out from their current anti-anginal medication and stabilized on a long acting nitrate such as, for example, nitroglycerin, isosorbide-5-mononitrate or isosorbide dinitrate. The term "washed out", when used in connection with this screen, means the withdrawal of current anti-anginal medication so that substantially all of said medication is eliminated from the body of the subject. A period of eight weeks is preferably allowed for both the wash out period and for the establishment of the subject on stable doses of said nitrate. Subjects having one or two attacks of angina per week while on stable doses of long acting nitrate are generally permitted to skip the wash out phase. After subjects are stabilized on nitrates, the subjects enter the randomization phase provided the subjects continue to have either one or two angina attacks per week. In the randomization phase, the

subjects are randomly placed into one of the four arms of the study set forth below. After completing the wash out phase, subjects in compliance with the entry criteria undergo twenty four hour ambulatory electrocardiogram (ECG) such as Holter monitoring, exercise stress testing such as a treadmill and evaluation of myocardial perfusion using PET (photon emission tomography) scanning to establish a baseline for each subject. When conducting a stress test, the speed of the treadmill and the gradient of the treadmill can be controlled by a technician. The speed of the treadmill and the angle of the gradient are generally increased during the test. The time intervals between each speed and gradient increase is generally determined using a modified Bruce Protocol.

After the baseline investigations have been completed, subjects are initiated on one of the following four arms of the study: (1) placebo; (2) atorvastatin calcium (about 2.5 mg to about 160 mg); (3) amlodipine besylate (about 2.5 mg to about 20 mg); or (4) a combination of the above doses of amlodipine besylate and atorvastatin calcium together. The subjects are then monitored for two to twenty four weeks. It will be recognized by a skilled person that the free base form or other salt forms of amlodipine besylate or the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of atorvastatin calcium and amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.

After the monitoring period has ended, subjects will undergo the following investigations: (1) twenty four hour ambulatory ECG, such as Holter monitoring; (2) exercise stress testing (e.g. treadmill using said modified Bruce Protocol); and (3) evaluation of myocardial perfusion using PET scanning. Patients keep a diary of painful ischemic events and nitroglycerine consumption. It is generally desirable to have an accurate record of the number of anginal attacks suffered by the patient during the duration of the test. Since a patient generally takes nitroglycerin to ease the pain of an anginal attack, the number of times that the patient administers nitroglycerine provides a reasonably accurate record of the number of anginal attacks.

To demonstrate the effectiveness of the drug combination of this invention, and to determine the dosage amounts of the drug combination of this invention, the person conducting the test will evaluate the subject using the tests described. Successful treatment will yield fewer instances of ischemic events as detected by ECG, will allow

the subject to exercise longer or at a higher intensity level on the treadmill, or to exercise without pain on the treadmill, or will yield better perfusion or fewer perfusion defects on photoemission tomography (PET).

The utility of the compounds of the present invention as medical agents in the treatment of hypertension and hyperlipidemia in mammals (e.g., humans) suffering from a combination of hypertension and hyperlipidemia is demonstrated by the activity of the compounds of this invention in conventional assays and the clinical protocol described below:

Effect of Amlodipine and Atorvastatin, Alone and in  
Combination, on the Treatment of Subjects Having  
Both Hypertension and Hyperlipidemia

This study is a double blind, parallel arm, randomized study to show the effectiveness of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof given in combination in controlling both hypertension and hyperlipidemia in subjects who have mild, moderate, or severe hypertension and hyperlipidemia.

Each subject is evaluated for 10 to 20 weeks and preferably for 14 weeks. Sufficient subjects are used in this screen to ensure that about 400 to 800 subjects are evaluated to complete the study.

**Entry criteria:** Subjects are male or female adults between 18 and 80 years of age having both hyperlipidemia and hypertension. The presence of hyperlipidemia is evidenced by evaluation of the low density lipoprotein (LDL) level of the subject relative to certain positive risk factors. If the subject has no coronary heart disease (CHD) and has less than two positive risk factors, then the subject is considered to have hyperlipidemia if the LDL of the subject is greater than or equal to 190. If the subject has no CHD and has two or more positive risk factors, then the subject is considered to have hyperlipidemia if the LDL of the subject is greater than or equal to 160. If the subject has CHD, then the subject is considered to have hyperlipidemia if the LDL of the subject is greater than or equal to 130.

Positive risk factors include (1) male over 45, (2) female over 55 wherein said female is not undergoing hormone replacement therapy (HRT), (3) family history of premature cardiovascular disease, (4) the subject is a current smoker, (5) the subject has diabetes, (6) an HDL of less than 45, and (7) the subject has hypertension. An HDL

of greater than 60 is considered a negative risk factor and will offset one of the above mentioned positive risk factors.

The presence of hypertension is evidenced by a sitting diastolic blood pressure (BP) of greater than 90 or sitting systolic BP of greater than 140. All blood pressures are generally determined as the average of three measurements taken five minutes apart.

Subjects are screened for compliance with the entry criteria set forth above. After all screening criteria are met, subjects are washed out from their current antihypertensive and lipid lowering medication and are placed on the NCEP ATP II Step 1 diet. The NCEP ATP II (adult treatment panel, 2nd revision) Step 1 diet sets forth the amount of saturated and unsaturated fat which can be consumed as a proportion of the total caloric intake. The term "washed out" where used in connection with this screen, means the withdrawal of current antihypertensive and lipid lowering medication so that substantially all of said medication is eliminated from the body of the subject. Newly diagnosed subjects generally remain untreated until the test begins. These subjects are also placed on the NCEP Step 1 diet. After the four week wash out and diet stabilization period, subjects undergo the following baseline investigations: (1) blood pressure and (2) fasting lipid screen. The fasting lipid screen determines baseline lipid levels in the fasting state of a subject. Generally, the subject abstains from food for twelve hours, at which time lipid levels are measured.

After the baseline investigations are performed subjects are started on one of the following: (1) a fixed dose of amlodipine besylate, generally about 2.5 to 10 mg; (2) a fixed dose of atorvastatin calcium, generally about 10 to 80mg; or (3) a combination of the above doses of amlodipine besylate and atorvastatin calcium together. Subjects remain on these doses for a minimum of six weeks, and generally for no more than eight weeks. It will be recognized by a skilled person that the free base form or other salt forms of amlodipine besylate or the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of atorvastatin calcium and amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved. The subjects return to the testing center at the conclusion of the six to eight weeks, so that the baseline evaluations can be repeated. The blood pressure of the subject at the conclusion of the study is compared with the blood pressure of the



subject upon entry. The lipid screen measures the total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apoB, VLDL (very low density lipoprotein) and other components of the lipid profile of the subject. Improvements in the values obtained after treatment relative to pretreatment values indicate the utility of the drug combination.

The utility of the compounds of the present invention as medical agents in the management of cardiac risk in mammals (e.g., humans) at risk for an adverse cardiac event is demonstrated by the activity of the compounds of this invention in conventional assays and the clinical protocol described below:

Effects of Amlodipine and Atorvastatin, Alone  
and in Combination, on Subjects at Risk  
of Future Cardiovascular Events

This study is a double blind, parallel arm, randomized study to show the effectiveness of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof given in combination are effective in reducing the overall calculated risk of future events in subjects who are at risk for having future cardiovascular events. This risk is calculated by using the Framingham Risk Equation. A subject is considered to be at risk of having a future cardiovascular event if that subject is more than one standard deviation above the mean as calculated by the Framingham Risk Equation. The study is used to evaluate the efficacy of a fixed combination of amlodipine and atorvastatin in controlling cardiovascular risk by controlling both hypertension and hyperlipidemia in patients who have both mild to moderate hypertension and hyperlipidemia.

Each subject is evaluated for 10 to 20 weeks and preferably for 14 weeks. Sufficient subjects are recruited to ensure that about 400 to 800 subjects are evaluated to complete the study.

Entry criteria: Subjects included in the study are male or female adult subjects between 18 and 80 years of age with a baseline five year risk which risk is above the median for said subject's age and sex, as defined by the Framingham Heart Study, which is an ongoing prospective study of adult men and women showing that certain risk factors can be used to predict the development of coronary heart disease. The age, sex, systolic and diastolic blood pressure, smoking habit, presence or absence of carbohydrate intolerance,

presence or absence of left ventricular hypertrophy, serum cholesterol and high density lipoprotein (HDL) of more than one standard deviation above the norm for the Framingham Population are all evaluated in determining whether a patient is at risk for adverse cardiac event. The values for the risk factors are inserted into the Framingham Risk equation and calculated to determine whether a subject is at risk for a future cardiovascular event.

Subjects are screened for compliance with the entry criteria set forth above. After all screening criteria are met, patients are washed out from their current antihypertensive and lipid lowering medication and any other medication which will impact the results of the screen. The patients are then placed on the NCEP ATP II Step 1 diet, as described above. Newly diagnosed subjects generally remain untreated until the test begins. These subjects are also placed on the NCEP ATP II Step 1 diet. After the four week wash out and diet stabilization period, subjects undergo the following baseline investigations: (1) blood pressure; (2) fasting; (3) lipid screen; (4) glucose tolerance test; (5) ECG; and (6) cardiac ultrasound. These tests are carried out using standard procedures well known to persons skilled in the art. The ECG and the cardiac ultrasound are generally used to measure the presence or absence of left ventricular hypertrophy.

After the baseline investigations are performed patients will be started on one of the following: (1) a fixed dose of amlodipine (about 2.5 to 10 mg); (2) a fixed dose of atorvastatin (about 10 to 80mg); or (3) the combination of the above doses of amlodipine and atorvastatin. It will be recognized by a skilled person that the free base form or other salt forms of amlodipine besylate or the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of atorvastatin calcium and amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved. Patients are kept on these doses and are asked to return in six to eight weeks so that the baseline evaluations can be repeated. At this time the new values are entered into the Framingham Risk equation to determine whether the subject has a lower, greater or no change in the risk of future cardiovascular event.

The above assays demonstrating the effectiveness of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof in the treatment of angina pectoris,

atherosclerosis, hypertension and hyperlipidemia together, and the management of cardiac risk, also provide a means whereby the activities of the compounds of this invention can be compared between themselves and with the activities of other known compounds. The results of these comparisons are useful for determining dosage levels in mammals, including humans, for the treatment of such diseases.

The following dosage amounts and other dosage amounts set forth elsewhere in the specification and in the appendant claims are for an average human subject having a weight of about 65 kg to about 70 kg. The skilled practitioner will readily be able to determine the dosage amount required for a subject whose weight falls outside the 65 kg to 70 kg range, based upon the medical history of the subject and the presence of diseases, e.g., diabetes, in the subject. All doses set forth herein, and in the appendant claims, are daily doses.

In general, in accordance with this invention, amlodipine besylate is generally administered in a dosage of about 2.5 mg to about 20 mg. Preferably, amlodipine besylate is administered in a dosage of about 5 mg to about 10 mg. It will be recognized by a skilled person that the free base form or other salt forms of amlodipine besylate may be used in this invention. Calculation of the dosage amount for these other forms of or the free base form or other salt forms of amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.

In general, in accordance with this invention, atorvastatin is administered in a dosage of about 2.5 mg to about 160 mg. Preferably, atorvastatin is administered in a dosage of about 10 mg to about 80 mg. It will be recognized by a skilled person that the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of or the free base form or other salt forms of atorvastatin calcium is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.

The compounds of the present invention are generally administered in the form of a pharmaceutical composition comprising at least one of the compounds of this invention together with a pharmaceutically acceptable carrier or diluent. Thus, the compounds of this invention can be administered either individually or together in any conventional oral, parenteral or transdermal dosage form.

For oral administration a pharmaceutical composition can take the form of solutions, suspensions, tablets, pills, capsules, powders, and the like. Tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the compounds of this invention can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

The combination of this invention may also be administered in a controlled release formulation such as a slow release or a fast release formulation. Such controlled release dosage formulations of the combination of this invention may be prepared using methods well known to those skilled in the art. The method of preferred administration will be determined by the attendant physician or other person skilled in the art after an evaluation of the subject's condition and requirements. The generally preferred formulation of amlodipine is Norvasc®. The generally preferred formulation of atorvastatin is Lipitor®.

For purposes of parenteral administration, solutions in sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions of the corresponding water-soluble salts. Such aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.

Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are known, or will be apparent in light of this disclosure, to

those skilled in this art. For examples, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 15th Edition (1975).

Pharmaceutical compositions according to the invention may contain 0.1%-95% of the compound(s) of this invention, preferably 1%-70%. In any event, the composition or formulation to be administered will contain a quantity of a compound(s) according to the invention in an amount effective to treat the condition or disease of the subject being treated.

Since the present invention relates to the treatment of diseases and conditions with a combination of active ingredients which may be administered separately, the invention also relates to combining separate pharmaceutical compositions in kit form. The kit includes two separate pharmaceutical compositions: amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof. The kit includes container means for containing the separate compositions such as a divided bottle or a divided foil packet, however, the separate compositions may also be contained within a single, undivided container. Typically the kit includes directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.

It should be understood that the invention is not limited to the particular embodiments described herein, but that various changes and modifications may be made without departing from the spirit and scope of this novel concept as defined by the following claims.

CLAIMS

1. A pharmaceutical composition comprising:
  - a. an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof;
  - b. an amount of atorvastatin or a pharmaceutically acceptable salt thereof; and
  - c. a pharmaceutically acceptable carrier or diluent.
2. A pharmaceutical composition of claim 1 comprising amlodipine besylate.
3. A pharmaceutical composition of claim 2 comprising the hemicalcium salt of atorvastatin.
4. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the sum of the antihypertensive and hypolipidemic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
5. A first pharmaceutical composition of claim 4 wherein said second pharmaceutical composition comprises amlodipine besylate.
6. A first pharmaceutical composition of claim 5 comprising the hemicalcium salt of atorvastatin.
7. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the sum of the antihypertensive and hypolipidemic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically

acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

8. A first pharmaceutical composition of claim 7 comprising amlodipine besylate.

9. A first pharmaceutical composition of claim 8 wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

10. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the antihypertensive and hypolipidemic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

11. A first pharmaceutical composition of claim 10 comprising amlodipine besylate.

12. A first pharmaceutical composition of claim 11 wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

13. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the antihypertensive and hypolipidemic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

14. A first pharmaceutical composition of claim 13 wherein said second pharmaceutical composition comprises amlodipine besylate.

15. A first pharmaceutical composition of claim 14 comprising the hemicalcium salt of atorvastatin.

16. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antiangina effect in a mammal suffering from angina pectoris, which effect is greater than the sum of the antiangina effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

17. A first pharmaceutical composition of claim 16 comprising amlodipine besylate.

18. A first pharmaceutical composition of claim 17 wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

19. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the sum of the antiangina effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

20. A first pharmaceutical composition of claim 19 wherein said second pharmaceutical composition comprises amlodipine besylate.

21. A first pharmaceutical composition of claim 20 comprising the hemicalcium salt of atorvastatin.

22. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the antianginal effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically



acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

acceptable carrier or diluent.

23. A first pharmaceutical composition of claim 22 comprising amlodipine besylate.

24. A first pharmaceutical composition of claim 23 wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

25. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the antianginal effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

26. A first pharmaceutical composition of claim 25 wherein said second pharmaceutical composition comprises amlodipine besylate.

27. A first pharmaceutical composition of claim 26 comprising the hemicalcium salt of atorvastatin.

28. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the sum of the antiatherosclerotic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

29. A first pharmaceutical composition of claim 28 wherein said second pharmaceutical composition comprises amlodipine besylate.

30. A first pharmaceutical composition of claim 29 comprising the hemicalcium salt of atorvastatin.

31. A composition of claim 30 wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.

32. A composition of claim 31 wherein said progression of atherosclerotic plaques is slowed in coronary arteries.

33. A composition of claim 31 wherein said progression of atherosclerotic plaques is slowed in carotid arteries.

34. A composition of claim 31 wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.

35. A composition of claim 30 wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.

36. A composition of claim 35 wherein said regression of atherosclerotic plaques occurs in coronary arteries.

37. A composition of claim 35 wherein said regression of atherosclerotic plaques occurs in carotid arteries.

38. A composition of claim 35 wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.

39. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the sum of the antiatherosclerotic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

40. A first pharmaceutical composition of claim 39 comprising amlodipine besylate.

41. A first pharmaceutical composition of claim 40 wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

42. A composition of claim 41 wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.

43. A composition of claim 42 wherein said progression of atherosclerotic plaques is slowed in coronary arteries.

44. A composition of claim 42 wherein said progression of atherosclerotic plaques is slowed in carotid arteries.

45. A composition of claim 42 wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.

46. A composition of claim 41 wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.

47. A composition of claim 46 wherein said regression of atherosclerotic plaques occurs in coronary arteries.

48. A composition of claim 46 wherein said regression of atherosclerotic plaques occurs in carotid arteries.

49. A composition of claim 46 wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.

50. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the antiatherosclerotic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

51. A first pharmaceutical composition of claim 50 comprising amlodipine besylate.

52. A first pharmaceutical composition of claim 51 wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

53. A composition of claim 52 wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.

54. A composition of claim 53 wherein said progression of atherosclerotic plaques is slowed in coronary arteries.

55. A composition of claim 53 wherein said progression of atherosclerotic plaques is slowed in carotid arteries.

56. A composition of claim 53 wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.

57. A composition of claim 52 wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.

58. A composition of claim 57 wherein said regression of atherosclerotic plaques occurs in coronary arteries.

59. A composition of claim 57 wherein said regression of atherosclerotic plaques occurs in carotid arteries.

60. A composition of claim 57 wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.

61. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the antiatherosclerotic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

62. A first pharmaceutical composition of claim 61 wherein said second pharmaceutical composition comprises amlodipine besylate.

63. A first pharmaceutical composition of claim 62 comprising the hemicalcium salt of atorvastatin.

64. A composition of claim 63 wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.

65. A composition of claim 64 wherein said progression of atherosclerotic plaques is slowed in coronary arteries.

66. A composition of claim 64 wherein said progression of atherosclerotic plaques is slowed in carotid arteries.

67. A composition of claim 64 wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.

68. A composition of claim 63 wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.

69. A composition of claim 68 wherein said regression of atherosclerotic plaques occurs in coronary arteries.

70. A composition of claim 68 wherein said regression of atherosclerotic plaques occurs in carotid arteries.

71. A composition of claim 68 wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.

72. A first pharmaceutical composition for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the sum of the cardiac risk management effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

73. A first pharmaceutical composition of claim 72 comprising amlodipine besylate.

74. A first pharmaceutical composition of claim 73 wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

75. A first pharmaceutical composition for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the sum of the cardiac risk management effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

76. A first pharmaceutical composition of claim 75 wherein said second pharmaceutical composition comprises amlodipine besylate.

77. A first pharmaceutical composition of claim 76 comprising the hemicalcium salt of atorvastatin.

78. A first pharmaceutical composition for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the cardiac risk management effects

achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.

79. A first pharmaceutical composition of claim 78 comprising amlodipine besylate.

80. A first pharmaceutical composition of claim 79 wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.

81. A first pharmaceutical composition for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the cardiac risk management effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

82. A first pharmaceutical composition of claim 81 wherein said second pharmaceutical composition comprises amlodipine besylate.

83. A first pharmaceutical composition of claim 82 comprising the hemicalcium salt of atorvastatin.

84. A kit for achieving a therapeutic effect in a mammal comprising:

- a. a therapeutically effective amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent in a first unit dosage form;
- b. a therapeutically effective amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and
- c. container means for containing said first and second dosage forms.

85. A kit of claim 84 comprising amlodipine besylate.

86. A kit of claim 85 comprising the hemicalcium salt of atorvastatin.
87. A kit of claim 86 wherein said therapeutic effect is treatment of hypertension and hyperlipidemia.
88. A kit of claim 86 wherein said therapeutic effect is treatment of angina pectoris.
89. A kit of claim 86 wherein said therapeutic effect is management of cardiac risk.
90. A kit of claim 86 wherein said therapeutic effect is treatment of atherosclerosis.
91. A kit of claim 90 wherein said treatment of atherosclerosis slows the progression of atherosclerotic plaques.
92. A kit of claim 91 wherein said progression of atherosclerotic plaques is slowed in coronary arteries.
93. A kit of claim 91 wherein said progression of atherosclerotic plaques is slowed in carotid arteries.
94. A kit of claim 91 wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.
95. A kit of claim 90 wherein said treatment of atherosclerosis causes the regression of atherosclerotic plaques.
96. A kit of claim 95 wherein said regression of atherosclerotic plaques occurs in coronary arteries.
97. A kit of claim 95 wherein said regression of atherosclerotic plaques occurs in carotid arteries.
98. A kit of claim 95 wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.
99. A method for treating a mammal in need of therapeutic treatment comprising administering to said mammal
- (a) an amount of a first compound, said first compound being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and
  - (b) an amount of a second compound, said second compound being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable carrier or diluent.

100. A method of claim 99 comprising amlodipine besylate.

101. A method of claim 100 comprising the hemicalcium salt of atorvastatin.

102. A method of claim 99 wherein said first compound and said second compound are administered simultaneously.

103. A method of claim 99 wherein said first compound and said second compound are administered sequentially in either order.

104. A method of claim 101 wherein said first compound and said second compound are administered simultaneously.

105. A method of claim 101 wherein said first compound and said second compound are administered sequentially in either order.

106. A method of claim 99 wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.

107. A method of claim 104 wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.

108. A method of claim 105 wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.

109. A method of claim 99 wherein said therapeutic treatment comprises antianginal treatment.

110. A method of claim 104 wherein said therapeutic treatment comprises antianginal treatment.

111. A method of claim 105 wherein said therapeutic treatment comprises antianginal treatment.

112. A method of claim 99 wherein said therapeutic treatment comprises cardiac risk management.

113. A method of claim 104 wherein said therapeutic treatment comprises cardiac risk management.

114. A method of claim 105 wherein said therapeutic treatment comprises cardiac risk management.

115. A method of claim 99 wherein said therapeutic treatment comprises antiatherosclerotic treatment.



116. A method of claim 104 wherein said therapeutic treatment comprises antiatherosclerotic treatment.

117. A method of claim 105 wherein said therapeutic treatment comprises antiatherosclerotic treatment.

ABSTRACT OF THE INVENTION

This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.

11 10  
12 09  
13 08  
14 07  
15 06  
16 05  
17 04  
18 03  
19 02  
20 01  
21 00  
22 99  
23 98  
24 97  
25 96  
26 95  
27 94  
28 93  
29 92  
30 91  
31 90  
32 89  
33 88  
34 87  
35 86  
36 85  
37 84  
38 83  
39 82  
40 81  
41 80  
42 79  
43 78  
44 77  
45 76  
46 75  
47 74  
48 73  
49 72  
50 71  
51 70  
52 69  
53 68  
54 67  
55 66  
56 65  
57 64  
58 63  
59 62  
60 61  
61 60  
62 59  
63 58  
64 57  
65 56  
66 55  
67 54  
68 53  
69 52  
70 51  
71 50  
72 49  
73 48  
74 47  
75 46  
76 45  
77 44  
78 43  
79 42  
80 41  
81 40  
82 39  
83 38  
84 37  
85 36  
86 35  
87 34  
88 33  
89 32  
90 31  
91 30  
92 29  
93 28  
94 27  
95 26  
96 25  
97 24  
98 23  
99 22  
100 21  
101 20  
102 19  
103 18  
104 17  
105 16  
106 15  
107 14  
108 13  
109 12  
110 11  
111 10  
112 09  
113 08  
114 07  
115 06  
116 05  
117 04  
118 03  
119 02  
120 01  
121 00  
122 99  
123 98  
124 97  
125 96  
126 95  
127 94  
128 93  
129 92  
130 91  
131 90  
132 89  
133 88  
134 87  
135 86  
136 85  
137 84  
138 83  
139 82  
140 81  
141 80  
142 79  
143 78  
144 77  
145 76  
146 75  
147 74  
148 73  
149 72  
150 71  
151 70  
152 69  
153 68  
154 67  
155 66  
156 65  
157 64  
158 63  
159 62  
160 61  
161 60  
162 59  
163 58  
164 57  
165 56  
166 55  
167 54  
168 53  
169 52  
170 51  
171 50  
172 49  
173 48  
174 47  
175 46  
176 45  
177 44  
178 43  
179 42  
180 41  
181 40  
182 39  
183 38  
184 37  
185 36  
186 35  
187 34  
188 33  
189 32  
190 31  
191 30  
192 29  
193 28  
194 27  
195 26  
196 25  
197 24  
198 23  
199 22  
200 21  
201 20  
202 19  
203 18  
204 17  
205 16  
206 15  
207 14  
208 13  
209 12  
210 11  
211 10  
212 09  
213 08  
214 07  
215 06  
216 05  
217 04  
218 03  
219 02  
220 01  
221 00  
222 99  
223 98  
224 97  
225 96  
226 95  
227 94  
228 93  
229 92  
230 91  
231 90  
232 89  
233 88  
234 87  
235 86  
236 85  
237 84  
238 83  
239 82  
240 81  
241 80  
242 79  
243 78  
244 77  
245 76  
246 75  
247 74  
248 73  
249 72  
250 71  
251 70  
252 69  
253 68  
254 67  
255 66  
256 65  
257 64  
258 63  
259 62  
260 61  
261 60  
262 59  
263 58  
264 57  
265 56  
266 55  
267 54  
268 53  
269 52  
270 51  
271 50  
272 49  
273 48  
274 47  
275 46  
276 45  
277 44  
278 43  
279 42  
280 41  
281 40  
282 39  
283 38  
284 37  
285 36  
286 35  
287 34  
288 33  
289 32  
290 31  
291 30  
292 29  
293 28  
294 27  
295 26  
296 25  
297 24  
298 23  
299 22  
300 21  
301 20  
302 19  
303 18  
304 17  
305 16  
306 15  
307 14  
308 13  
309 12  
310 11  
311 10  
312 09  
313 08  
314 07  
315 06  
316 05  
317 04  
318 03  
319 02  
320 01  
321 00  
322 99  
323 98  
324 97  
325 96  
326 95  
327 94  
328 93  
329 92  
330 91  
331 90  
332 89  
333 88  
334 87  
335 86  
336 85  
337 84  
338 83  
339 82  
340 81  
341 80  
342 79  
343 78  
344 77  
345 76  
346 75  
347 74  
348 73  
349 72  
350 71  
351 70  
352 69  
353 68  
354 67  
355 66  
356 65  
357 64  
358 63  
359 62  
360 61  
361 60  
362 59  
363 58  
364 57  
365 56  
366 55  
367 54  
368 53  
369 52  
370 51  
371 50  
372 49  
373 48  
374 47  
375 46  
376 45  
377 44  
378 43  
379 42  
380 41  
381 40  
382 39  
383 38  
384 37  
385 36  
386 35  
387 34  
388 33  
389 32  
390 31  
391 30  
392 29  
393 28  
394 27  
395 26  
396 25  
397 24  
398 23  
399 22  
400 21  
401 20  
402 19  
403 18  
404 17  
405 16  
406 15  
407 14  
408 13  
409 12  
410 11  
411 10  
412 09  
413 08  
414 07  
415 06  
416 05  
417 04  
418 03  
419 02  
420 01  
421 00  
422 99  
423 98  
424 97  
425 96  
426 95  
427 94  
428 93  
429 92  
430 91  
431 90  
432 89  
433 88  
434 87  
435 86  
436 85  
437 84  
438 83  
439 82  
440 81  
441 80  
442 79  
443 78  
444 77  
445 76  
446 75  
447 74  
448 73  
449 72  
450 71  
451 70  
452 69  
453 68  
454 67  
455 66  
456 65  
457 64  
458 63  
459 62  
460 61  
461 60  
462 59  
463 58  
464 57  
465 56  
466 55  
467 54  
468 53  
469 52  
470 51  
471 50  
472 49  
473 48  
474 47  
475 46  
476 45  
477 44  
478 43  
479 42  
480 41  
481 40  
482 39  
483 38  
484 37  
485 36  
486 35  
487 34  
488 33  
489 32  
490 31  
491 30  
492 29  
493 28  
494 27  
495 26  
496 25  
497 24  
498 23  
499 22  
500 21  
501 20  
502 19  
503 18  
504 17  
505 16  
506 15  
507 14  
508 13  
509 12  
510 11  
511 10  
512 09  
513 08  
514 07  
515 06  
516 05  
517 04  
518 03  
519 02  
520 01  
521 00  
522 99  
523 98  
524 97  
525 96  
526 95  
527 94  
528 93  
529 92  
530 91  
531 90  
532 89  
533 88  
534 87  
535 86  
536 85  
537 84  
538 83  
539 82  
540 81  
541 80  
542 79  
543 78  
544 77  
545 76  
546 75  
547 74  
548 73  
549 72  
550 71  
551 70  
552 69  
553 68  
554 67  
555 66  
556 65  
557 64  
558 63  
559 62  
560 61  
561 60  
562 59  
563 58  
564 57  
565 56  
566 55  
567 54  
568 53  
569 52  
570 51  
571 50  
572 49  
573 48  
574 47  
575 46  
576 45  
577 44  
578 43  
579 42  
580 41  
581 40  
582 39  
583 38  
584 37  
585 36  
586 35  
587 34  
588 33  
589 32  
590 31  
591 30  
592 29  
593 28  
594 27  
595 26  
596 25  
597 24  
598 23  
599 22  
600 21  
601 20  
602 19  
603 18  
604 17  
605 16  
606 15  
607 14  
608 13  
609 12  
610 11  
611 10  
612 09  
613 08  
614 07  
615 06  
616 05  
617 04  
618 03  
619 02  
620 01  
621 00  
622 99  
623 98  
624 97  
625 96  
626 95  
627 94  
628 93  
629 92  
630 91  
631 90  
632 89  
633 88  
634 87  
635 86  
636 85  
637 84  
638 83  
639 82  
640 81  
641 80  
642 79  
643 78  
644 77  
645 76  
646 75  
647 74  
648 73  
649 72  
650 71  
651 70  
652 69  
653 68  
654 67  
655 66  
656 65  
657 64  
658 63  
659 62  
660 61  
661 60  
662 59  
663 58  
664 57  
665 56  
666 55  
667 54  
668 53  
669 52  
670 51  
671 50  
672 49  
673 48  
674 47  
675 46  
676 45  
677 44  
678 43  
679 42  
680 41  
681 40  
682 39  
683 38  
684 37  
685 36  
686 35  
687 34  
688 33  
689 32  
690 31  
691 30  
692 29  
693 28  
694 27  
695 26  
696 25  
697 24  
698 23  
699 22  
700 21  
701 20  
702 19  
703 18  
704 17  
705 16  
706 15  
707 14  
708 13  
709 12  
710 11  
711 10  
712 09  
713 08  
714 07  
715 06  
716 05  
717 04  
718 03  
719 02  
720 01  
721 00  
722 99  
723 98  
724 97  
725 96  
726 95  
727 94  
728 93  
729 92  
730 91  
731 90  
732 89  
733 88  
734 87  
735 86  
736 85  
737 84  
738 83  
739 82  
740 81  
741 80  
742 79  
743 78  
744 77  
745 76  
746 75  
747 74  
748 73  
749 72  
750 71  
751 70  
752 69  
753 68  
754 67  
755 66  
756 65  
757 64  
758 63  
759 62  
760 61  
761 60  
762 59  
763 58  
764 57  
765 56  
766 55  
767 54  
768 53  
769 52  
770 51  
771 50  
772 49  
773 48  
774 47  
775 46  
776 45  
777 44  
778 43  
779 42  
780 41  
781 40  
782 39  
783 38  
784 37  
785 36  
786 35  
787 34  
788 33  
789 32  
790 31  
791 30  
792 29  
793 28  
794 27  
795 26  
796 25  
797 24  
798 23  
799 22  
800 21  
801 20  
802 19  
803 18  
804 17  
805 16  
806 15  
807 14  
808 13  
809 12  
810 11  
811 10  
812 09  
813 08  
814 07  
815 06  
816 05  
817 04  
818 03  
819 02  
820 01  
821 00  
822 99  
823 98  
824 97  
825 96  
826 95  
827 94  
828 93  
829 92  
830 91  
831 90  
832 89  
833 88  
834 87  
835 86  
836 85  
837 84  
838 83  
839 82  
840 81  
841 80  
842 79  
843 78  
844 77  
845 76  
846 75  
847 74  
848 73  
849 72  
850 71  
851 70  
852 69  
853 68  
854 67  
855 66  
856 65  
857 64  
858 63  
859 62  
860 61  
861 60  
862 59  
863 58  
864 57  
865 56  
866 55  
867 54  
868 53  
869 52  
870 51  
871 50  
872 49  
873 48  
874 47  
875 46  
876 45  
877 44  
878 43  
879 42  
880 41  
881 40  
882 39  
883 38  
884 37  
885 36  
886 35  
887 34  
888 33  
889 32  
890 31  
891 30  
892 29  
893 28  
894 27  
895 26  
896 25  
897 24  
898 23  
899 22  
900 21  
901 20  
902 19  
903 18  
904 17  
905 16  
906 15  
907 14  
908 13  
909 12  
910 11  
911 10  
912 09  
913 08  
914 07  
915 06  
916 05  
917 04  
918 03  
919 02  
920 01  
921 00  
922 99  
923 98  
924 97  
925 96  
926 95  
927 94  
928 93  
929 92  
930 91  
931 90  
932 89  
933 88  
934 87  
935 86  
936 85  
937 84  
938 83  
939 82  
940 81  
941 80  
942 79  
943 78  
944 77  
945 76  
946 75  
947 74  
948 73  
949 72  
950 71  
951 70  
952 69  
953 68  
954 67  
955 66  
956 65  
957 64  
958 63  
959 62  
960 61  
961 60  
962 59  
963 58  
964 57  
965 56  
966 55  
967 54  
968 53  
969 52  
970 51  
971 50  
972 49  
973 48  
974 47  
975 46  
976 45  
977 44  
978 43  
979 42  
980 41  
981 40  
982 39  
983 38  
984 37  
985 36  
986 35  
987 34  
988 33  
989 32  
990 31  
991 30  
992 29  
993 28  
994 27  
995 26  
996 25  
997 24  
998 23  
999 22  
1000 21  
1001 20  
1002 19  
1003 18  
1004 17  
1005 16  
1006 15  
1007 14  
1008 13  
1009 12  
1010 11  
1011 10  
1012 09  
1013 08  
1014 07  
1015 06  
1016 05  
1017 04  
1018 03  
1019 02  
1020 01  
1021 00  
1022 99  
1023 98  
1024 97  
1025 96  
1026 95  
1027 94  
1028 93  
1029 92  
1030 91  
1031 90  
1032 89  
1033 88  
1034 87  
1035 86  
1036 85  
1037 84  
1038 83  
1039 82  
1040 81  
1041 80  
1042 79  
1043 78  
1044 77  
1045 76  
1046 75  
1047 74  
1048 73  
1049 72  
1050 71  
1051 70  
1052 69  
1053 68  
1054 67  
1055 66  
1056 65  
1057 64  
1058 63  
1059 62  
1060 61  
1061 60  
1062 59  
1063 58  
1064 57  
1065 56  
1066 55  
1067 54  
1068 53  
1069 52  
1070 51  
1071 50  
1072 49  
1073 48  
1074 47  
1075 46  
1076 45  
1077 44  
1078 43  
1079 42  
1080 41  
1081 40  
1082 39  
1083 38  
1084 37  
1085 36  
1086 35  
1087 34  
1088 33  
1089 32  
1090 31  
1091 30  
1092 29  
1093 28  
1094 27  
1095 26  
1096 25  
1097 24  
1098 23  
1099 22  
1100 21  
1101 20  
1102 19  
1103 18  
1104 17  
1105 16  
1106 15  
1107 14  
1108 13  
1109 12  
1110 11  
1111 10  
1112 09  
1113 08  
1114 07  
1115 06  
1116 05  
1117 04  
1118 03  
1119 02  
1120 01  
1121 00  
1122 99  
1123 98  
1124 97  
1125 96  
1126 95  
1127 94  
1128 93  
1129 92  
1130 91  
1131 90  
1132 89  
1133 88  
1134 87  
1135 86  
1136 85  
1137 84  
1138 83  
1139 82  
1140 81  
1141 80  
1142 79  
1143 78  
1144 77  
1145 76  
1146 75  
1147 74  
1148 73  
1149 72  
1150 71  
1151 70  
1152 69  
1153 68  
1154 67  
1155 66  
1156 65  
1157 64  
1158 63  
1159 62  
1160 61  
1161 60  
1162 59  
1163 58  
1164 57  
1165 56  
1166 55  
1167 54  
1168 53  
1169 52  
1170 51  
1171 50  
1172 49  
1173 48  
1174 47  
1175 46  
1176 45  
1177 44  
1178 43  
1179 42  
1180 41  
1181 40  
1182 39  
1183 38  
1184 37  
1185 36  
1186 35  
1187 34  
1188 33  
1189 32  
1190 31  
1191 30  
1192 29  
1193 28  
1194 27  
1195 26  
1196 25  
1197 24  
1198 23  
1199 22  
1200 21  
1201 20  
1202 19  
1203 18  
1204 17  
1205 16  
1206 15  
1207 14  
1208 13  
1209 12  
1210 11  
1211 10  
1212 09  
1213 08  
1214 07  
1215 06  
1216 05  
1217 04  
1218 03  
1219 02  
1220 01  
1221 00  
1222 99  
1223 98  
1224 97  
1225 96  
1226 95  
1227 94  
1228 93  
1229 92  
1230 91  
1231 90  
1232 89  
1233 88  
1234 87  
1235 86  
1236 85  
1237 84  
1238 83  
1239 82  
1240 81  
1241 80  
1242 79  
1243 78  
1244 77  
1245 76  
1246 75  
1247 74  
1248 73  
1249 72  
1250 71  
1251 70  
1252 69  
1253 68  
1254 67  
1255 66  
1256 65  
1257 64  
1258 63  
1259 62  
1260 61  
1261 60  
1262 59  
1263 58  
1264 57  
1265 56  
1266 55  
1267 54  
1268 53  
1269 52  
1270 51  
1271 50  
1272 49  
1273 48  
1274 47  
1275 46  
1276 45  
1277 44  
1278 43  
1279 42  
1280 41  
1281 40  
1282 39  
1283 38  
1284 37  
1285 36  
1286 35  
1287 34  
1288 33  
1289 32  
1290 31  
1291 30  
1292 29  
1293 28  
1294 27  
1295 26  
1296 25  
1297 24  
1298 23  
1299 22  
1300 21  
1301 20  
1302 19  
1303 18  
1304 17  
1305 16  
1306 15  
1307 14  
1308 13  
1309 12  
1310 11  
1311 10  
1312 09  
1313 08  
1314 07  
1315 06  
1316 05  
1317 04  
1318 03  
1319 02  
1320 01  
1321 00  
1322 99  
1323 98  
1324 97  
1325 96  
1326 95  
1327 94  
1328 93  
1329 92  
1330 91  
1331 90  
1332 89  
1333 88  
1334 87  
1335 86  
1336 85  
1337 84  
1338 83  
1339 82  
1340 81  
1341 80  
1342 79  
1343 78  
1344 77  
1345 76  
1346 75  
1347 74  
1348 73  
1349 72  
1350 71  
1351 70  
1352 69  
1353 68  
1354 67  
1355 66  
1356 65  
1357 64  
1358 63  
1359 62  
1360 61  
1361 60  
1362 59  
1363 58  
1364 57  
1365 56  
1366 55  
1367 54  
1368 53  
1369 52  
1370 51  
1371 50  
1372 49  
1373 48  
1374 47  
1375 46  
1376 45  
1377 44  
1378 43  
1379 42  
1380 41  
1381 40  
1382 39  
1383 38  
1384 37  
1385 36  
1386 35  
1387 34  
1388 33  
1389 32  
1390 31  
1391 30  
1392 29  
1393 28  
1394 27  
1395 26  
1396 25  
1397 24  
1398 23  
1399 22  
1400 21  
1401 20  
1402 19  
1403 18  
1404 17  
1405 16  
1406 15  
1407 14  
1408 13  
1409 12  
1410 11  
1411 10  
1412 09  
1413 08  
1414 07  
1415 06  
1416 05  
1417 04  
1418 03  
1419 02  
1420 01  
1421 00  
1422 99  
1423 98  
1424 97  
1425 96  
1426 95  
1427 94  
1428 93  
1429 92  
1430 91  
1431 90  
1432 89  
1433 88  
1434 87  
1435 86  
1436 85  
1437 84  
1438 83  
1439 82  
1440 81  
1441 80  
1442 79  
1443 78  
1444 77  
1445 76  
1446 75  
1447 74  
1448 73  
1449 72  
1450 71  
1451 70  
1452 69  
1453 68  
1454 67  
1455 66  
1456 65  
1457 64  
1458 63  
1459 62  
1460 61  
1461 60  
1462 59  
1463 58  
1464 57  
1465 56  
1466 55  
1467 54  
1468 53  
1469 52  
1470 51  
1471 50  
1472 49  
1473 48  
1474 47  
1475 46  
1476 45